These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 7459239

  • 1. Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.
    Leake RE, Laing L, Calman KC, Macbeth FR, Crawford D, Smith DC.
    Br J Cancer; 1981 Jan; 43(1):59-66. PubMed ID: 7459239
    [Abstract] [Full Text] [Related]

  • 2. Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis.
    Leake RE, Laing L, McArdle C, Smith DC.
    Br J Cancer; 1981 Jan; 43(1):67-71. PubMed ID: 7459240
    [Abstract] [Full Text] [Related]

  • 3. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.
    Henry JA, Nicholson S, Hennessy C, Lennard TW, May FE, Westley BR.
    Br J Cancer; 1990 Jan; 61(1):32-8. PubMed ID: 2153395
    [Abstract] [Full Text] [Related]

  • 4. Activated oestrogen receptors in breast cancer and response to endocrine therapy.
    Fernandez MD, Burn JI, Sauven PD, Parmar G, White JO, Myatt L.
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):41-6. PubMed ID: 6537914
    [Abstract] [Full Text] [Related]

  • 5. The prediction of hormonal dependency of mammary cancer.
    Block GE, Jensen EV, Polley TZ.
    Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. DNA/protein ratio as an index of oestrogen receptor content in human breast cancer.
    Muñoz J, Bolufer P, Rodriguez A, Antonio P, Vazquez C.
    Eur J Cancer Clin Oncol; 1983 Sep; 19(9):1207-12. PubMed ID: 6684567
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Heterogeneity of soluble and nuclear oestrogen receptor status of involved nodes in relation to primary breast cancer.
    Castagnetta L, Traina A, Di Carlo A, Latteri AM, Carruba G, Leake RE.
    Eur J Cancer Clin Oncol; 1987 Jan; 23(1):31-5. PubMed ID: 3595683
    [Abstract] [Full Text] [Related]

  • 16. Breast cancer prognosis in three different racial groups in relation to steroid hormone receptor status.
    Pegoraro RJ, Nirmul D, Reinach SG, Jordaan JP, Joubert SM.
    Breast Cancer Res Treat; 1986 Jan; 7(2):111-8. PubMed ID: 3719113
    [Abstract] [Full Text] [Related]

  • 17. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J.
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The prognosis of breast cancer patients in relation to the oestrogen receptor status of both primary disease and involved nodes.
    Castagnetta L, Traina A, Carruba G, Fecarotta E, Palazzotto G, Leake R.
    Br J Cancer; 1992 Jul; 66(1):167-70. PubMed ID: 1637667
    [Abstract] [Full Text] [Related]

  • 20. Triple hormone-receptor assay: a more accurate predictive tool for the treatment of advanced breast cancer?
    Barnes DM, Skinner LG, Ribeiro GG.
    Br J Cancer; 1979 Dec; 40(6):862-5. PubMed ID: 230853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.